SELECT Trial Summary: Semaglutide for Cardiovascular Outcomes

Design

Randomized, double-blind, placebo-controlled, event-driven cardiovascular outcomes trial enrolling 17,604 adults aged ≥45 with BMI ≥27, established cardiovascular disease (prior MI, stroke, or symptomatic PAD), and no diabetes. Participants received once-weekly subcutaneous semaglutide 2.4 mg or placebo. Median follow-up: 39.8 months (~3.3 years).

Primary result

The primary endpoint — a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3-point MACE) — occurred in 6.5% of semaglutide participants vs. 8.0% of placebo participants.

Hazard ratio: 0.80 (95% CI, 0.72–0.90; P < 0.001).

This represents a 20% relative risk reduction in major adverse cardiovascular events.

Key secondary outcomes

• Cardiovascular death: HR 0.85 (not individually significant)
• Non-fatal MI: HR 0.72 — the strongest component reduction
• Non-fatal stroke: HR 0.93
• All-cause death: HR 0.81 (nominally significant, P = 0.01 in hierarchical testing)
• Mean weight change: −9.4% with semaglutide vs. −0.9% with placebo

Adverse events

Gastrointestinal events led to discontinuation in 16.6% of semaglutide participants vs. 8.2% on placebo. Serious adverse events were balanced between groups. No increase in pancreatitis, thyroid cancer, or pancreatic cancer was observed.

Interpretation

SELECT fundamentally expanded semaglutide's clinical relevance beyond weight loss and diabetes. Three paradigm-shifting implications:

1. Cardiovascular benefit independent of diabetes — previous GLP-1 cardiovascular outcomes trials (SUSTAIN-6, LEADER) enrolled diabetic populations. SELECT demonstrated MACE reduction in non-diabetic patients, establishing cardiovascular protection as a class effect of GLP-1 agonists independent of glucose metabolism.
2. Weight loss as cardiovascular medicine — the 20% MACE reduction establishes pharmacologic weight loss as a legitimate cardiovascular intervention, comparable in magnitude to statins in their original landmark trials.
3. Broadened indication — based on SELECT, the FDA approved semaglutide 2.4 mg for cardiovascular risk reduction in adults with overweight/obesity and established CVD — a new indication beyond weight management.

Clinical significance

SELECT positioned GLP-1 receptor agonists as cardiometabolic drugs rather than merely anti-obesity agents. The 20% MACE reduction in a high-risk population without diabetes makes cardiovascular protection the most clinically compelling reason to prescribe semaglutide in patients with established CVD and overweight, regardless of their weight-loss goals.